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Abstract: Along of widespread application of anti-cancer drug Gefitinib (GEF), it appears in human
body fluids as well as clinical wastewater. Consequently, a reliable and easy-to-adapt detection
technique is of essential importance to quantify the drug in different media. The extraction and
quantitative detection of anti-cancer drug Gefinitib (GEF) is demonstrated based on a straightforward
and efficient magnetic nanoparticle-assisted preconcentration route from water and human plasma
samples. Iron oxide magnetic nanoparticles (Fe3O4) have been prepared with an average particle
size of 15 nm and utilized as extractible adsorbents for the magnetic solid-phase extraction (MSPE)
of GEF in aqueous media. The method is based on MSPE and preconcentration of GEF followed
by High-Performance Liquid Chromatography-Ultraviolet Detection (HPLC-UV). The yield of GEF
extraction under the optimum MSPE conditions were 94% and 87% for water and plasma samples,
respectively. The chromatographic separation was carried out isocratically at 25 ◦C on a Phenomenex
C8 reversed phase column (150 mm × 4.6 mm, with 5 µm particle size). The proposed method was
linear over concentration ranges of 15.0–300.0 and 80.0–600.0 ng/mL for water and plasma samples
with limits of detection of 4.6 and 25.0 ng/mL in a respective order. Relative standard deviations
(%RSD) for intra-day and inter-day were 0.75 and 0.94 for water samples and 1.26 and 1.70 for plasma
samples, respectively. Using the magnetic nanoparticles (MNPs) as loaded drug-extractors made the
detection of the anti-cancer drug environmentally friendly and simple and has great potential to be
used for different drug-containing systems.
Keywords: gefitinib; magnetic solid-phase extraction; iron oxide nanoparticles; human plasma;
liquid chromatography
1. Introduction
Gefitinib is an anti-tumor drug that is used widespread and plays an important role in cancer
therapy. It inhibits the intracellular phosphorylation of numerous tyrosine kinases associated
with transmembrane cell surface receptors, including the tyrosine kinases associated with the
epidermal growth factor receptor (EGFR-TK). Gefitinib has antineoplastic activity, and has been
approved for the treatment of non-small cell lung cancer (NSCLC) [1]. The chemical name of
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gefitinib is N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
corresponding to the molecular formula C22H24ClFN4O3. The chemical structure of gefitinib is shown
in Figure 1. Gefitinib is described in the Ph. Eur. monograph 2866 [2]. Its solubility in water increases
with decreasing pH [2]. The molecule has two pKa of 5.4 and 7.2 and its partition coefficient logP is
3.75 (octanol/water) [2]. IRESSA® (gefitinib tablets) contains 250 mg of gefitinib and is available as
brown film-coated tablets for daily oral administration. It is absorbed slowly after oral administration
with mean bioavailability of 60%. Elimination is by metabolism (primarily CYP 3A4) and excretion in
feces [3]. During the application of Gefitinib, it appears not only in the human body but in clinical
wastewater as well; thus, efforts towards the detection and separation of this compound are of
great importance.
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aimed at determining Gefitinib by HPLC-UV after magnetic solid-phase extraction (MSPE), which is 
a relatively new promising technique for the preparation of analytical samples and has gained 
considerable attention [13–15]. This method opens up new routes towards the separation of drugs 
from medical wastewater as well as the detection of the anticancer drugs in human samples. 
Using MSPE, the preconcentration of analytes from large volumes can be carried out by means 
of magnetic sorbents. Magnetite nanoparticles (Fe3O4) are excellent candidates for the above-
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previously reported works.  
Figure 1. Chemical stru re of Gefitinib.
Consequently, there is an essential demand for the development of sensitive analytical methods
for the detection and evaluation of Gefitinib as an important antineoplastic drug with strong potency.
Numerous analytical methods hav already been developed for t e quantitative determination
of Gefitinib using spectrophotometry [4,5], High-Performance Liquid Chromat grap y-Ultraviolet
Detection (HPLC-UV) [6–8], HPLC-MS/MS [9–11] and UHPLC-MS/MS [12]. However, our method is
aimed at determining Gefitinib by HPLC-UV after magnetic solid-phase extraction (MSPE), which
is a relatively new promising technique for the prepar tion of analytical samples and has gained
considerable atte tion [13–15]. This method open up new routes towards the separatio of drugs
from medical wastewater as well as the detection of the anticancer drugs in human samples.
Using MSPE, the preconcentration of analytes from large volumes can be carried out by means of
magnetic sorbents. Magnetite nanoparticles (Fe3O4) are ex ellent candidates for the bov -mentioned
purposes and en ble a greatly simplified sample pretreatment using MSPE since the phase separation
can be quickly and easily accomplished by applying an external magnetic field [13]. In this study,
the method for the preparation and the application of aqueous, surfactant-coated Fe3O4 MNPs as
novel sorbents for the SPE of Gefitinib from water and plasma samples. To the best of our knowledge,
this is the first study that uses Fe3O4 NPs as an extraction agent for Gefitinib from water and human
plasma samples. Table 1 highlights the main features of our method compared to various, previously
reported works.
Table 1. Comparison of the proposed method with other reported methods to determine Gefitinib
(GEF) in different sample matrices.
Matrix Extraction Method DetectionSystem
Extraction
Time (min)
LOD
(ng/mL)
Linear Range
(ng/mL) %RSD Ref.
Water SPE HPLC-UV 20 4.6 15–300 1.0 This work
Human Plasma SPE HPLC-UV 20 25.0 80–600 1.1 This work
Polymeric
nano-formulation - HPLC-UV - 37.8 200–1200 <1 [6]
Tablet - HPLC-UV - 90 5000–25,000 0.877 [16]
Human Plasma LLE HPLC-MS 15 - 5–3000 <5 [17]
Human Plasma Protein precipitation HPLC-MS 10 - 1–1000 <15 [18]
Rat Plasma Protein precipitation HPLC-MS 10 - 5–1000 <15 [18]
Human Plasma LLE LC-MS/MS >30 - 0.5–1000 <15 [19]
LOD: limit of detection; RSD: relative standard deviation; SPE: solid-phase extraction; LLE: liquid–liquid extraction.
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2. Materials and Methods
2.1. Chemicals and Reagents
Gefitinib was kindly obtained from Pfizer Inc. (New York, NY, USA) (certified to have a purity of
>99%). Ethanol (EtOH, ≥99.8% for HPLC), acetonitrile (ACN, ≥99.9% for HPLC), methanol (MeOH,
≥99.9% for HPLC), iron(II) chloride tetrahydrate (FeCl2·4H2O, ≥99.0%), potassium hydroxide (KOH,
>85%) and trichloroacetic acid (Cl3CCOOH, ≥99.0%) were purchased from Sigma-Aldrich (Darmstadt,
Germany). Iron(III) chloride hexahydrate (FeCl3·6H2O, >99.0%) was supplied by Fluka (Buchs,
Switzerland). Sodium dihydrogen phosphate (NaH2PO4, ≥98%), sodium dodecyl sulphate (SDS,
≥99%) and orthophosphoric acid (H3PO4, ≥98%) were obtained from Adwic Chemical Company (Cairo,
Egypt). All chemicals and reagents were of analytical grade and used without further modification.
Ultrapure water (Milli-Q with a resistivity of 18.2 MΩ·cm) was used for the synthesis and purification
of nanoparticles and double-distilled water was used during the study. Human plasma samples were
collected from one patient treated with Iressa tablets at Mansoura University Oncology Centre. Pooled
blank plasma was obtained from Mansoura University Hospitals (Mansoura, Egypt) and was kept
frozen until use after gentle thawing. The study was conducted in accordance with the Declaration
of Helsinki, and the protocol was approved by the Research Ethical Committee (REC) of Faculty of
Pharmacy, Mansoura University (Date of REC protocol approval: 27/06/2018) under the code number
(2018-47). The research work conducted on human has been approved on 29/03/2020 under the code
number: 2020-34. Sample donors signed a consent form approved by the Ethics Committee of Faculty
of Pharmacy, Mansoura University.
2.2. Measurement Methods
The characterization of the nanoparticles was performed using Zetasizer Nano ZSP (Malvern
Panalytical, Malvern, UK) equipped with a 633-nm laser, a JEOL JSM-6700F Field-Emission Scanning
Electron Microscope (FE-SEM, operated at 5 kV, Tokyo, Japan) and a Tecnai G2 F20 TMP Transmission
Electron Microscope (TEM, operated at 200 kV, FEI, Hillsboro, OR, USA). The crystal structure of
the nanoparticles was performed by a Bruker AXS D8 Advance X-ray diffractometer (XRD) using a
Cu-Kα1,2 radiation source. Chromatographic separations were carried out on a Shimadzu HPLC system
(Kyoto, Japan) consisting of a degasser unit (DGU-20 A3R), a pump (LC-20 AT), an injection valve
with a 20-µL sample loop, a column oven (CTO-20 A) and a UV detector (SPD-20 A). The separations
were carried out on a Hyper Clone C8 column (150 mm × 4.6 mm, with 5 µm particle size) from
Phenomenex (Torrance, CA, USA). The mobile phase consisted of acetonitrile: 0.3% phosphoric
acid in a ratio of 35:65, the pH was adjusted to 3 with triethylamine. The analysis was done under
isocratic conditions at a flow rate of 0.8 mL/min and the detection was performed at 345 nm. For data
processing and acquisition, LabSolutions software version 5.84 from Shimadzu was used. A Jenway
6850 UV/Vis Spectrophotometer (Stone, UK) was applied for the absorbance measurements of the
solutions. An ultrasonic cleaner set (WUC-D06H) (Seoul, Korea) and a pH Meter from Jenway 3505
(Stone, UK) were used.
2.3. Synthesis of Fe3O4 Nanoparticles
Fe3O4 nanoparticles were synthesized via the chemical co-precipitation method partly published
elsewhere [20] but applying modifications and optimization. Briefly, in a 25-mL volumetric flask,
0.165 g FeCl2·4H2O and 0.225 g FeCl3·6H2O were dissolved in ultrapure water and completed to the
mark. Simultaneously, 25 mL of 0.9 M KOH was prepared. The Fe2+/Fe3+ mixture was then heated to
80 ◦C in a rounded three neck flask under N2 gas bubbling and vigorously stirred for 15 min. The KOH
solution was then added drop wisely (6.25 mL/min) form a black precipitate of Fe3O4 nanoparticles.
The formed precipitate was kept for another 15 min under N2 gas at the same temperature. Finally,
the obtained Fe3O4 nanoparticles were collected and washed with 50 mL Milli-Q water four times to
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remove any residue of KOH and unreacted precursor. The synthesized NPs were characterized by
Dynamic Light Scattering (DLS), XRD, FE-SEM and TEM.
2.4. Optimum Conditions for MSPE of Gefitinib
The magnetic solid-phase extraction of gefitinib was performed in 5-mL volume Wassermann
tubes, 300 µL from Gefitinib stock solution (200.0 µg/mL) was added to 150 µL of sodium dodecyl
sulphate (SDS) (2 mg/mL) and then 0.5 mg of Fe3O4 nanoparticles was added. Finally, the volume was
completed to 3 mL with phosphate buffer (pH = 3). The prepared mixture was vortexed for 1 min
and then kept for 25 min under sonication for complete extraction. To separate Fe3O4 nanoparticles
from the solution, an external magnet (Nd-Fe-B, (6 × 2 × 1 cm3)) was placed under the vial to separate
the magnetite while the upper solution was decanted. Finally, Gefitinib was desorbed again from
the nanoparticles’ surface by adding 3 mL and 0.5 mL ethanol for UV spectroscopy and HPLC
measurements, respectively, followed by sonication for 30 s.
2.5. Extraction of GEF from Water and Plasma Samples
The developed MSPE method was applied for the extraction and determination of GEF from
water as well as plasma samples. The extraction of GEF from all samples was done according to MSPE
procedure described in the “Optimization of MSPE mechanism and procedure” section. However, an
additional purification step was carried out on the plasma samples before extraction. A total of 1 mL of
[ethanol: 10% trichloroacetic acid (1:1 v/v)] was added to 0.5 mL plasma followed by the centrifugation
of the mixture in order to precipitate plasma proteins. MSPE was then applied on the clear supernatant
containing the drug. The final elution of the analyte was carried out with 0.5 mL ethanol prior to the
injection into the HPLC column.
3. Results and Discussion
3.1. Characterization of the Synthesized Fe3O4 Magnetic Nanoparticles
The size of the synthesized Fe3O4 magnetic nanoparticles was characterized by scanning electron
microscopy (SEM) and transmission electron microscopy (TEM). In Figure 2, SEM and TEM images
show the average particle size of 19 ± 4 nm with narrow size distribution, which was confirmed
by DLS as well (Polydispersity index (PdI) = 0.15). This size of the nanocrystals were found to
be reproducible over different batches. Figure 3 shows the diffraction pattern of the nanoparticles
indicating that the structure of the synthesized nanoparticles matches the reference of magnetite phase
(Fe3O4). The stability of the colloidal solution was proven by measuring the ζ-potential that was found
to be +14 mV.
3.2. Optimization of MSPE Mechanism and Procedure
The MSPE mechanism was chosen as reported in the previous methods [21–23]. It is based
on the formation of SDS-coated magnetic nanoparticles’ mixed hemimicelles/admicelles, which was
found to be an effective technique for the adsorption of ionic and non-ionic species. There are two
possible phenomena for the attraction between the target analyte and the SDS-coated MNPs. The first
one relies on the fact that at certain pH, the SDS-coated MNPs possess a negative charge that can
electrostatically attract the positively charged analyte at this pH [21]. The second one is due to
hydrophobic attraction into the formed hemimicelles/admicelles system [24]. Considering that the zeta
potential of the nanoparticles changed from +14 to –20 mV, both mechanisms can be anticipated to
take place simultaneously. After loading the MNPs with the target analyte, it can be easily separated
from the solution by either centrifugation or applying an external magnet. Finally, the desorption of
the analyte from the MNPs’ surface back to the solution can be instantly obtained by adding some
organic solvents, such as methanol, ethanol or acetonitrile. The mechanism of the analyte adsorption
and desorption can be seen in Scheme 1.
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Scheme 1. Schematics of the interaction between the analyte and the MNP surface during adsorption
and desorption.
Different conditions aff cting the MSPE procedure w re studied, such as the effect of sample
pH, adsorption time, the amount of adsorbent, the amount of SDS, desorption time and the type of
desorbing solvent. The effect of the above-mentioned factors was studied based on measuring the
absorbance of the sample before and after the adsorption on the SDS-coated MNPs. HPLC-UV was
used at the final application step for the validation of the method and for the analysis of the real
samples. Series of (5 mL) glass tubes were used throughout the study for easy collection and handling
of the samples. Scheme 2 represents the process of the extraction and detection of the analyte.
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3.2.1. Effect of the Sample’s pH
Since the attractive interaction between our target analyte and the SDS-coated MNPs is anticipated
to be mainly electrostatic, the pH of the sample plays a critical role in the extraction process. At different
pH values, the ionization of Gefitinib and the SDS hemimicelles/admicelles changes [25]. At very low
pH, the free protons in the solution can be attracted to the negatively charged hemimicelles/admicelles
and decrease its negative charge value, and, as a result, the targeted electrostatic attraction between
SDS hemimicelles and the nanoparticles will be declined. Simultaneously, we should consider the
ionization of Gefitinib, which was found to possess a full positive charge at pH values less than 6 [25].
On the other hand, at higher pH, OH− ions can be attracted to the surface of Fe3O4 nanoparticles and
hinder the formation of the SDS the hemimicelles/admicelles system [21]. So, theoretically, we have
considered the optimum pH for extraction to be in the range of 2 to 4, which equals a Gefitinib charge
of +2. We have studied different pH values ranging from 2 to 8 (adjusted by 0.2 M phosphate buffer) as
shown in (Figure 4A), and pH 3 was found to be the optimum condition.
3.2.2. Effect of Concentration of SDS
Another critical factor that needed to be carefully studied was the SDS concentration. As was
mentioned before, the mechanism of adsorption depends on the formation of SDS hemimicelles
or admicelles on the surface of Fe3O4 nanoparticles, which can be obtained by SDS concentrations
above its critical aggregation concentration (CAC) [26]. Different concentrations of the SDS were
studied in the range of 10.0–300.0 µg/mL as shown in Figure 4B. In the absence of SDS, GEF hardly
adsorbed on the surface of Fe3O4 nanoparticles. However, the adsorption of GEF on the surface of
the SDS-coated MNPs increased with increasing concentrations of SDS to a certain point (point of
formation of hemimicelles/admicelles), which was found to be 100 µg/mL. At concentrations greater
than 100.0 µg/mL, the adsorbed amount started to decrease gradually until it completely disappeared at
a concentration of 300 µg/mL. The reason can be explained as, at higher concentrations, the SDS-micelles
started to be formed in the bulk solution, which can compete with the adsorption of GEF. Therefore,
100.0 µg/mL was chosen as the optimum concentration of SDS in later studies.
3.2.3. Effect of Amount of Adsorbent
The amount of adsorbent added was studied in the range of 0.2–2.0 mg (Figure 4C). The adsorption
of GEF gradually increased by increasing the amount of adsorbent until a maximum value at 0.5 mg
of MNPs. Above this concentration, increasing the amount of MNPs showed no further increase in
the adsorption. Consequently, 0.5 mg was found to be the optimum amount added to extract GEF
completely from a 3-mL solution volume.
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3.2.4. Effect of Extraction Time
Figure 4D shows the effect of extraction time on the adsorption of GEF i the range of 1–30 min.
It can be see that GEF adsorption increased gradually up to 25 min and then saturated. Based on the
characteristic of the adsorption behavior, the optimal extraction time was found to be 25 min.
3.2.5. Desorption Conditions
The desorption of our target analyte from the surface of the SDS-coated MNPs can be obtained
by adding organic solvents as reported in previous works [24,27–29]. It was found that organic
solvents can disrupt the formed hemimicelles/ dmicelles, which diminishes the available place for GEF
adsorption. Acetonitrile, methanol and ethanol was studied as different desorbing s lvents, ethanol
was chosen as it resulted in the highest extraction efficiency. Desorption time was studied as well; only
30 s was enough for the complete desorption of the analyte.
3.2.6. Extraction Procedure from Spiked Plasma Samples
Under the optimum MSPE conditions, the extraction of GEF directly from spiked plasma samples
was challenging. As for a complex matrix such as plasma, there are various components expected to be
present (for example proteins, ions, nutrient molecules and wastes) that can compete with the target
analyte on adsorption to the surface of the nanoparticles. Therefore, an additional protein precipitation
step was added to the procedure. Firstly, solely acetonitrile was used to precipitate plasma proteins;
however, the recovery was not satisfactory. On the other hand, using a mixture of ethanol and 10%
trichloroacetic acid in a ratio of 1:1 (v/v) resulted in a higher percent recovery reaching 87 ± 1%.
3.3. Analytical Performance
The proposed method was applied for the quantitative analysis of the drug in water and plasma
samples. Method validation was accomplished by testing linearity and range, the limit of quantification
(LOQ), the limit of detection (LOD), accuracy, precision, and specificity according to International
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Conference on Harmonisation (ICH) recommendations [30]. Table 2 illustrates the quantitative
parameters of the proposed method. The calibration curves were linear over the ranges of 15 to 300 and
80 to 600 ng/mL for water and plasma samples, respectively. The LOD values for water and plasma
samples were 4.6 and 25 ng/mL, respectively. LOQ and LOD were calculated according to ICH Q2R1
recommendations [30].
LOD = 3.3Sa/b (1)
LOQ = 10Sa/b (2)
where Sa is the standard deviation of the intercept and b is the slope of the calibration curve.
Table 2. Analytical performance data of the proposed method for extraction and determination of GEF
from water and plasma samples.
Matrix
LOD
(ng/mL)
LOQ
(ng/mL)
%RSD
%Error
Extraction
Percentage (%)
Linear Range
(ng/mL) R
2
Intra-Day Inter-Day
Water 4.6 15.0 0.8 0.9 0.55 94.0 15–300 0.9999
Human
plasma 25.5 80.0 1.3 1.7 0.60 87.1 80–600 0.9997
Intra-day and inter-day precision were studied using the following three different concentrations:
50.0, 150.0 and 300.0 ng/mL for water samples and 150.0, 450.0 and 600.0 ng/mL for plasma samples.
The relative standard deviations (%RSD) for intra-day and inter-day were 0.75 and 0.94 for water samples
and 1.26 and 1.70 for plasma samples, respectively (results summarized in Table 3). Method specificity
was tested by comparing chromatograms of blank water and plasma samples with the spiked ones,
no peaks appeared at the same retention time of GEF. Figure 5 shows typical chromatograms obtained
from the determination of GEF by the proposed method in spiked plasma samples. The recovery
of the analyte was 94.0 ± 1.0% and 87.1 ± 1.0% from water and plasma samples, respectively.
The results indicate high sensitivity, good precision, wide linear range and satisfactory recoveries of
the proposed method.
Table 3. Precision data for the determination of GEF in water and plasma samples by the
proposed method.
Intra-Day Precision Inter-Day Precision
Conc.
Taken
(ng/mL)
Conc.
Found
(ng/mL)
% Found
Conc.
Taken
(ng/mL)
Conc.
Found
(ng/mL)
% Found
Water
samples
50.00 50.62 101.24 50.00 50.62 101.24
150.00 151.99 101.33 150.00 152.63 101.75
300.00 299.97 99.99 300.00 299.76 99.92
X ± SD 100.85 ± 0.75 100.95 ± 0.94
%RSD 0.75 0.94
%Error 0.43 0.54
Plasma
samples
150.00 147.76 98.51 150.00 149.86 99.91
450.00 454.54 101.01 450.00 452.43 100.54
600.00 596.94 99.49 600.00 584.16 97.36
X ± SD 99.67 ± 1.26 99.27 ± 1.70
%RSD 1.26 1.70
%Error 0.73 0.98
N.B. Each result is the average of three separate determinations.
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3.4. Application of the Proposed Method to the Real Plasma Sample
The proposed method was successfully adapted and applied for the determination of GEF in
spiked and real plasma samples with satisfactory recovery equal to 87%. The method was tested for its
ability to determine the analyte in a real plasma sample obtained from patient treated with GEF.
The sample was collected at peak plasma concentration (Cmax) [3] after 4 h from administration
of a single dose of Iressa tablet (250.0 mg). The developed extraction procedure was applied on the
collected plasma sample, and the area under the peak obtained after sample injection into the HPLC
column was then used to calculate sample concentration. The unknown sample concentration was
132.0 ng/mL which is found to be within the reported Cmax range [31] (48.7–324.0 ng/mL).
3.5. Comparison with Other Reported Methods
Based on the literature review, the HPLC-UV methodology was mostly used for assessing GEF in
bulk and pharmaceutical dosage forms. However, more sensitive methodologies, such as HPLC/MS
and UPLC/MS, were frequently used for the determination of our target analyte in complex matrices
for example human plasma. The proposed HPLC-UV method showed a wide linear range in both
water and plasma samples with very low LODs and LOQs comparable with those obtained from
previously reported HPLC/MS methods. Table 1 in the introduction highlights the main features of our
method compared to other, previously reported studies.
4. Conclusions
A novel SPE method for the preconcentration, detection and quantification of GEF in water and
plasma samples based on SDS-coated magnetic nanoparticles mixed hemimicelles/admicelles was
developed. The targeted analyte was collected and extracted from water and human plasma samples
by means of aqueous Fe3O4 nanoparticles acting as easily extractable carriers loaded by the drug on
their surface. The extraction method is clean and environmentally friendly, as it does not use any
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toxic, hazardous or expensive materials. Through the magnetic features and high surface-to-volume
ratio of MNPs, the separation procedure was simple and resulted in high extraction capacity within
short time using a straightforward and simple magnet. Sample preconcentration prior to HPLC-UV
analysis as well as the simple and effective drug desorption resulted in greatly reduced LODs and
LOQs compared to other reported methods. The proposed method is sensitive, simple and suitable for
the fast determination of GEF in water and plasma samples and opens up possibilities to be extended
for extracting and detecting different drugs in various media.
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